ClinicalTrials.gg
CompletedNCT01491672RECORD-4Updated Jun 6, 2016Results posted

Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma

A Phase 2 interventional study of RAD001 in Metastatic Renal Cell Carcinoma, sponsored by Novartis Pharmaceuticals. Completed at 17 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-06.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
134
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies testing everolimus in Carcinoma, Renal Cell — 4 open to participants now, 7 under way, 2 of them phase 3. Everolimus · Carcinoma, Renal Cell.

Enrollment
8th of 48
134 · median 46
Started
2011
with 9 others
Phase 2
26 of 48
2 open now
Registered
30th of 48
by date
Lead sponsor
9 of 48
Novartis Pharmaceuticals

Among the 48 studies testing everolimus in Carcinoma, Renal Cell, this one is the 8th largest by enrollment, is one of 10 that started in 2011, is one of 26 in phase 2, and was the 30th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

4 of the 48 studies testing everolimus in Carcinoma, Renal Cell are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About everolimus

Everolimus: first FDA approval 2009 (AFINITOR), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing everolimus in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

This study will evaluate everolimus as second-line therapy in patients with metastatic renal cell carcinoma. Each patient will be enrolled and stratified in one of three cohorts based upon their first-line therapy: 1) prior cytokines, 2) prior sunitinib, or 3) prior anti-VEGF therapy other than sunitinib.

03

Conditions studied

  • Metastatic Renal Cell Carcinoma

Keywords

  • Metastatic Renal Cell Carcinoma
  • Second Line
  • Everolimus
  • RAD001
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years old.
  2. Patients with advanced renal cell carcinoma of a histological or cytological confirmation of clear cell (or with a component of clear cell) renal carcinoma that have previously progressed on or were intolerant to therapy with sunitinib, sorafenib, pazopanib, axitinib, bevacizumab, or cytokine therapy.
  3. Patients must have had prior nephrectomy (partial or total).
  4. Patients with at least one at baseline as per the 1.0 criteria. If skin lesions are reported as target lesions, they should be documented (at baseline and at every physical exam) using color photography and a measuring device (such as a caliper) in clear focus to allow the size of the lesion(s) to be determined from the photograph.
  5. Patients with a Performance Status ≥ 70%.
  6. Adequate bone marrow function as shown by:

    1. ≥ 1.5 x 109/L,
    2. ≥ 100 x 109/L,
    3. >9 g/dL
  7. Adequate liver function as shown by:

    1. Serum ≤ 1.5 x ,
    2. and AST ≤ 2.5 x ULN. Patients with known liver may enroll if their AST and ALT ≤ 5 x ULN,
    3. \< 1.3 (INR \< 3 in patients treated with anticoagulants)
  8. Adequate renal function: serum creatinine ≤ 2.0 x ULN.
  9. Fasting serum cholesterol ≤300 mg/dl OR ≤7.75 mmol/L AND fasting triglycerides ≤2.5 x ULN.
  10. Written obtained before any trial related activity and according to local guidelines.

Exclusion criteria

Exclusion Criteria:

  1. Patients with .
  2. Patients within 4 weeks post-major surgery (e.g., intra-thoracic, intra-abdominal or intrapelvic), open , or significant traumatic injury to avoid wound healing complications.

    Minor procedures and percutaneous biopsies or placement of vascular access device require 7 days prior to study entry.

  3. Patients in anticipation of the need for major surgical procedure during the course of the study.
  4. Patients who had radiation therapy within 4 weeks prior to start of study treatment (palliative radiotherapy to bone lesions allowed up to 2 weeks prior to study treatment start).
  5. Patients with a serious non-healing wound, ulcer, or bone fracture.
  6. Patients with a history of seizure(s) not controlled with standard medical therapy.
  7. Patients who have received more than one prior treatment regimen for renalcell carcinoma
  8. Patients who have received therapy for RCC
  9. Patients who have previously received systemic mTOR inhibitors (eg, sirolimus, temsirolimus, everolimus)
  10. Patients with a known to everolimus or other rapamycins (eg, sirolimus, temsirolimus) or to its .
  11. History or clinical evidence of central nervous system (CNS) metastases.
  12. gastrointestinal abnormalities including, but not limited to:

    1. Malabsorption syndrome:
    2. Major resection of the stomach or small bowel that could affect the absorption of study drug
    3. Active peptic ulcer disease
    4. Inflammatory bowel disease:

    i. Ulcerative colitis, or other gastrointestinal conditions with increased risk of perforation ii. History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess within 28 days prior to beginning study treatment.

  13. Patients with a known history of seropositivity. Screening for HIV infection at baseline is not required.
  14. Active bleeding diathesis
  15. Uncontrolled diabetes mellitus as defined by fasting serum glucose > 2.0 x .
  16. Patients who have any severe and/or uncontrolled medical conditions such as:

    1. unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction

      ≤ 6 months prior to enrollment, serious uncontrolled cardiac arrhythmia,

    2. active or uncontrolled severe infection,
    3. history of invasive fungal infections,
    4. severe hepatic impairment ( class C),
    5. severely impaired lung function
  17. History of cerebrovascular accident (CVA) including (TIA) ≤ 6 months before start of study treatment.
  18. History of pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months. Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible.
  19. Patients who have a history of another primary and off treatment for ≤ 3 years, with the exception of non-melanoma skin cancer and carcinoma in situ of the uterine cervix or breast, and localized cancer of the bladder (T1) and prostate (T1 - T2).
  20. Female patients who are pregnant or nursing (lactating).
  21. Adults of who are not using effective methods.

    Adequate contraceptives must be used throughout the trial and for 8 weeks after last study drug administration in female patients. Women of must have a negative serum pregnancy test within 7 days prior to first administration of study drug.

  22. Patients who are using other agents or who had received investigational drugs ≤ 2 weeks prior to study treatment start. This should not include sunitinib, sorafenib, axitinib, pazopanib and cytokines.
  23. Patients unwilling or unable to comply with the protocol.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
134 participants (actual)

Study arms

  • Experimental
    RAD001

    Participants, received RAD001 10 mg orally once daily.

    Drug: RAD001

Interventions

  • DrugRAD001

    Study drug was supplied as 5 mg tablets in blister packs.

    Also known as: Everolimus

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) - All Participants

    PFS during second-line treatment was defined as the time from the date of enrollment to the date of the first documented disease progression or death due to any cause. The primary analysis of PFS was based on a local radiology review of CT scans and MRI collected until the participant experienced disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0.

    Time frame: 20 months

Secondary outcomes

  1. Duration of PFS for Each First-line Treatment Cohort

    Duration of PFS during second-line treatment was defined as the time from the date of enrollment to the date of the first documented disease progression or death due to any cause. Participants' assessment was based on the local radiological data according to the RECIST 1.0 Criteria.

    Time frame: 20 months

  2. Overall Survival (OS)

    OS was defined as the time from date of enrollment to date of death due to any cause.

    Time frame: 28 months

  3. Clinical Benefit Rate (CBR)

    CBR was defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR) or stable disease based on the local radiological data according to the RECIST 1.0 criteria.

    Time frame: 20 months

  4. Objective Response Rate (ORR)

    ORR was defined as the proportion of participants with best overall response of CR or PR based on the local radiological data according to the RECIST 1.0 Criteria

    Time frame: 20 months

  5. Duration of Response (DoR)

    DoR was defined as the time from the first occurrence of PR or CR (as per local radiological review) until the date of the first documented disease progression or death due to underlying cancer.

    Time frame: 20 months

07

Results

Posted Jun 2, 2016

Participant flow

This was an open-label study where all eligible participants were enrolled into one of 3 cohorts based upon prior first-line therapy.

Participant flow — Overall Study
MilestonePrior SunitinibOther Prior Vascular Endothelial Growth Factor (VEGF)Prior Cytokines
Started586214
Safety set586114
Completed223
Not completed566011
Withdrew: Lost to follow-up041
Withdrew: Withdrawal by subject670
Withdrew: Adverse event8104
Withdrew: Disease progression42346
Withdrew: Protocol deviation010
Withdrew: Death040

Outcome measures

PrimaryProgression-free Survival (PFS) - All Participants

PFS during second-line treatment was defined as the time from the date of enrollment to the date of the first documented disease progression or death due to any cause. The primary analysis of PFS was based on a local radiology review of CT scans and MRI collected until the participant experienced disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0.

Time frame:
20 months
Reported as:
Median · months
Progression-free Survival (PFS) - All Participants
monthsAll Participants
Progression-free Survival (PFS) - All Participants7.4 (5.6 to 10.5)
SecondaryDuration of PFS for Each First-line Treatment Cohort

Duration of PFS during second-line treatment was defined as the time from the date of enrollment to the date of the first documented disease progression or death due to any cause. Participants' assessment was based on the local radiological data according to the RECIST 1.0 Criteria.

Time frame:
20 months
Reported as:
Median · months
Duration of PFS for Each First-line Treatment Cohort
monthsPrior SunitinibOther Prior Vascular Endothelial Growth Factor (VEGF)Prior Cytokines
Duration of PFS for Each First-line Treatment Cohort5.6 (3.7 to 11.3)7.8 (5.7 to 11.0)12.9 (2.6 to NA)
SecondaryOverall Survival (OS)

OS was defined as the time from date of enrollment to date of death due to any cause.

Time frame:
28 months
Reported as:
Median · months
Overall Survival (OS)
monthsPrior SunitinibOther Prior Vascular Endothelial Growth Factor (VEGF)Prior CytokinesAll Participants
Overall Survival (OS)23.8 (13.7 to NA)17.2 (11.9 to NA)NA (15.9 to NA)23.8 (17.0 to NA)
SecondaryClinical Benefit Rate (CBR)

CBR was defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR) or stable disease based on the local radiological data according to the RECIST 1.0 criteria.

Time frame:
20 months
Reported as:
Number · Participants
Clinical Benefit Rate (CBR)
ParticipantsPrior SunitinibOther Prior Vascular Endothelial Growth Factor (VEGF)Prior CytokinesAll Participants
Clinical Benefit Rate (CBR)414811100
SecondaryObjective Response Rate (ORR)

ORR was defined as the proportion of participants with best overall response of CR or PR based on the local radiological data according to the RECIST 1.0 Criteria

Time frame:
20 months
Reported as:
Number · Participants
Objective Response Rate (ORR)
ParticipantsPrior SunitinibOther Prior Vascular Endothelial Growth Factor (VEGF)Prior CytokinesAll Participants
Objective Response Rate (ORR)43310
SecondaryDuration of Response (DoR)

DoR was defined as the time from the first occurrence of PR or CR (as per local radiological review) until the date of the first documented disease progression or death due to underlying cancer.

Time frame:
20 months
Reported as:
Median · months
Duration of Response (DoR)
monthsPrior SunitinibOther Prior Vascular Endothelial Growth Factor (VEGF)Prior CytokinesAll Participants
Duration of Response (DoR)10.8 (9.2 to NA)7.4 (3.3 to 9.2)9.2 (NA to NA)9.2 (3.3 to NA)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Prior Sunitinib—13/58 (22.4%)28/58 (48.3%)
Other Prior Anti VEGF—16/61 (26.2%)33/61 (54.1%)
Prior Cytokines—3/14 (21.4%)12/14 (85.7%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventPrior SunitinibOther Prior Anti VEGFPrior Cytokines
Cardiac failureCardiac disorders0/580/611/14
Lower limb fractureInjury, poisoning and procedural complications0/580/611/14
Pleural fibrosisRespiratory, thoracic and mediastinal disorders0/580/611/14
Respiratory failureRespiratory, thoracic and mediastinal disorders1/583/610/14
Abdominal painGastrointestinal disorders2/580/610/14
CellulitisInfections and infestations2/580/610/14
PneumoniaInfections and infestations2/580/610/14
SepsisInfections and infestations2/581/610/14
AnaemiaBlood and lymphatic system disorders0/582/610/14
Multi-organ failureGeneral disorders1/582/610/14
Most frequent other events
Showing 10 of 29
Most frequent other events
EventPrior SunitinibOther Prior Anti VEGFPrior Cytokines
StomatitisGastrointestinal disorders5/588/615/14
AnaemiaBlood and lymphatic system disorders8/588/614/14
HypercholesterolaemiaMetabolism and nutrition disorders3/583/612/14
HypertriglyceridaemiaMetabolism and nutrition disorders3/584/612/14
DiarrhoeaGastrointestinal disorders5/581/610/14
PyrexiaGeneral disorders2/585/611/14
HyperglycaemiaMetabolism and nutrition disorders3/585/611/14
Iron deficiency anaemiaBlood and lymphatic system disorders0/581/611/14
Mouth ulcerationGastrointestinal disorders2/582/611/14
FatigueGeneral disorders0/582/611/14

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Prior SunitinibOther Prior Vascular Endothelial Growth Factor (VEGF)Prior CytokinesTotal
Mean56.0 ± 12.0656.5 ± 11.1460.3 ± 10.5956.7 ± 11.48
Sex: Female, Male
Sex: Female, Male(Participants)Prior SunitinibOther Prior Vascular Endothelial Growth Factor (VEGF)Prior CytokinesTotal
Female1522643
Male4340891
08

Study locations

17 sites
  • Memorial Sloan Kettering Cancer Center
    NY, New York 90033, United States
  • Novartis Investigative Site
    Rio Negro, Viedma 8500, Argentina
  • Novartis Investigative Site
    Tucuman, T4000, Argentina
  • Novartis Investigative Site
    Florianopolis, SC 88034-000, Brazil
  • Novartis Investigative Site
    Barretos, SP 14784-400, Brazil
  • Novartis Investigative Site
    São Paulo, SP 01246-000, Brazil
  • Novartis Investigative Site
    São Paulo, SP 01509-900, Brazil
  • Novartis Investigative Site
    Sofia, 1784, Bulgaria
  • Novartis Investigative Site
    Beijing, Beijing 100730, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310003, China
  • Novartis Investigative Site
    Beijing, 100021, China
  • Novartis Investigative Site
    Guangzhou, 510060, China
  • Novartis Investigative Site
    Shanghai, 200032, China
  • Novartis Investigative Site
    Leningrad Region, Russia 188663, Russian Federation
  • Novartis Investigative Site
    Moscow, Russia 125284, Russian Federation
  • Novartis Investigative Site
    Nizhny Novgorod, Russia 603001, Russian Federation
  • Novartis Investigative Site
    Obninsk, Russia 249036, Russian Federation
09

References and documents

Publications

  • Yang L, Alyasova A, Ye D, Ridolfi A, Dezzani L, Motzer RJ. RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis. BMC Cancer. 2018 Feb 17;18(1):195. doi: 10.1186/s12885-018-4091-5. PubMed 29454306 ↗
  • Motzer RJ, Alyasova A, Ye D, Karpenko A, Li H, Alekseev B, Xie L, Kurteva G, Kowalyszyn R, Karyakin O, Neron Y, Cosgriff T, Collins L, Brechenmacher T, Lin C, Morgan L, Yang L. Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4). Ann Oncol. 2016 Mar;27(3):441-8. doi: 10.1093/annonc/mdv612. Epub 2015 Dec 17. PubMed 26681676 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2011
First posted
Dec 14, 2011
Start
Nov 2011
Primary completionActual
May 2015
CompletionActual
May 2015
Results first posted
Jun 2, 2016
Last update
Jun 6, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01491672
Responsible party
Sponsor
First posted
Dec 14, 2011
Start date
Nov 2011
Primary completion
May 2015
Completion
May 2015
Results posted
Jun 2, 2016
Last update
Jun 6, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion